{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sickle-cell-disease/management/contraception/","result":{"pageContext":{"chapter":{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception","depth":2,"htmlHeader":"<!-- begin field c346d208-aead-4e9b-b4b2-6f658553e397 --><h2>Scenario: Contraception</h2><!-- end field c346d208-aead-4e9b-b4b2-6f658553e397 -->","summary":"Covers recommendations for the use of contraception in women with sickle cell disease.","htmlStringContent":"<!-- begin item 08cce656-8b23-422c-99e4-7cdd1bd22456 --><!-- begin field b345835c-326b-4631-91e4-acbd0088613a --><p>From age 13 years onwards.</p><!-- end field b345835c-326b-4631-91e4-acbd0088613a --><!-- end item 08cce656-8b23-422c-99e4-7cdd1bd22456 -->","topic":{"id":"eb346bd0-1df2-5db2-a583-a366e34cfc19","topicId":"cc107f5d-efe6-4625-840e-5c4d4656869b","topicName":"Sickle cell disease","slug":"sickle-cell-disease","lastRevised":"Last revised in November 2016","chapters":[{"id":"d2b6d668-4d29-5c50-b65d-7467cbcce2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47f9af8d-8bda-55a3-bf81-eb75a7c4f02a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a0ece3e-fa44-5ecd-9f55-ac17384d960c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"44a5b5f9-fc8e-5024-87e3-a7e42dca3dd9","slug":"changes","fullItemName":"Changes"},{"id":"48757ec5-731a-57fd-8e39-d2cdf918179a","slug":"update","fullItemName":"Update"}]},{"id":"53ae2089-f545-5b24-99c5-a9fc620ea575","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ffff20e4-5bc5-5c3b-bb59-858dba2fcf8d","slug":"goals","fullItemName":"Goals"},{"id":"16f85d1d-aec7-5173-9e0b-7d9456bdf3a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12a41d5f-f447-5a64-868a-7648c7de9355","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5de2a0f3-a77d-5244-a401-dbd2cbcfefb3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fc893fb4-51ec-5705-8dff-c7fba1969646","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cc1cc5c4-df13-5e74-bde0-9f625ec4d1cf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"02e2bd4f-75cd-5b59-9a81-c06d3bcf4d2f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a8eb5f7-6691-505b-bd86-9620102057a3","slug":"definition","fullItemName":"Definition"},{"id":"b756c83a-dcc0-5792-b3f9-fa9416929ce3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"488c0ab1-f1c0-5fbf-bd1e-e327181c2e1f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b62a5aae-0dc3-5ac0-a1b1-d3ca0a7969ac","slug":"complications","fullItemName":"Complications"}]},{"id":"9336c0e7-d5d3-5dd6-99fd-50610ced96e1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dd5a2bec-36ce-58c0-b0f1-4ec5d4d17c21","slug":"when-to-suspect-sickle-cell-disease","fullItemName":"When to suspect sickle cell disease"},{"id":"bdbf4e2a-7a0c-5a2e-8b9c-4a9c661409ef","slug":"diagnosis-of-sickle-cell-disease","fullItemName":"Diagnosis of sickle cell disease"},{"id":"68746f0d-607a-5db5-8949-a87a4ed29328","slug":"when-to-suspect-an-acute-sickle-cell-crisis","fullItemName":"When to suspect an acute sickle cell crisis"},{"id":"ed48dbda-a404-50cf-a290-86fafcdb9908","slug":"assessment-of-acute-crisis","fullItemName":"Assessment of acute crisis"}]},{"id":"221fb88b-b951-5835-b282-ed218b637ff0","fullItemName":"Management","slug":"management","subChapters":[{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening"},{"id":"1da4d393-99a4-51c1-b354-f1742b9d8b1f","slug":"management-sickle-cell-crisis","fullItemName":"Scenario: Management - sickle cell crisis"},{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications"},{"id":"4493185d-8907-5325-a195-a7cd7039bd68","slug":"prevention-of-complications","fullItemName":"Scenario: Prevention of complications"},{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait"},{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception"}]},{"id":"a424bf70-c56c-54a4-a2e2-019ab7c27c69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2148be5b-6502-5e45-b86b-e552aa3226fd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a46384b-d43c-536a-9a17-4b8953d8457a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"46873f42-ab32-5894-b2fe-429a4e62161b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd24310-b8ac-5381-b51a-ca1f6c178d72","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7405fe0a-8432-5e64-9fe0-4d112fd89232","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"221fb88b-b951-5835-b282-ed218b637ff0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"88a0736c-8be5-5114-bf5b-150ca156ad31","slug":"contraception","fullItemName":"Contraception","depth":3,"htmlHeader":"<!-- begin field a88e9b9f-1ce5-4166-a31f-cf0220ca150c --><h3>Which contraception is suitable for women with sickle cell disease?</h3><!-- end field a88e9b9f-1ce5-4166-a31f-cf0220ca150c -->","summary":null,"htmlStringContent":"<!-- begin item 02807768-3fc4-433f-b0ff-ec9abe4bd5b0 --><!-- begin field a84a008c-cb65-4a6d-81a3-9bddf4b67679 --><p><strong>When advising on contraception, consider the potential harms in the context of the benefits (that is, preventing potentially serious <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/background-information/complications/\">complications</a></strong><strong> caused by pregnancy in a woman with sickle cell disease).</strong></p><ul><li><strong>In general, women with sickle cell disease without complications can use any method of contraception.</strong> <ul><li><strong>Options include:</strong><ul><li>Combined hormomal contraceptives (pill, patch, or vaginal ring). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for detailed information on these methods of contraception.</li><li>Progestogen-only contraception (pill, implant, or injectable). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a> for detailed information on these methods of contraception.</li><li>Intrauterine contraception (levonorgestrel intrauterine system [LNG-IUS] or copper intrauterine devices [Cu-IUD]). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a> for detailed information on these methods of contraception.</li><li>Surgical sterilization. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-sterilization/\">Contraception - sterilization</a> for detailed information on this method of contraception.</li><li>Barrier methods. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-barrier-methods-spermicides/\">Contraception - barrier methods and spermicides</a> for detailed information on this method of contraception.</li></ul></li><li><strong>However, advise the woman to</strong> consider using a long-acting reversible contraception (Cu-IUD, LNG-IUS, progestogen-only injectables, progestogen-only implant, or the combined hormonal vaginal ring), as they provide a highly reliable and effective method of contraception (failure rate less than 1 pregnancy per 100 women in a year).</li><li><strong>Be aware that:</strong><ul><li>Combined hormonal contraceptives are contraindicated in women with <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-pulmonary-hypertension\">pulmonary hypertension</a>, which present in up to a third of people with sickle cell disease. </li><li>Progestogen-only contraception may have a beneficial effect on symptoms (such as painful crises) and increase the proportion of fetal haemoglobin (which has a protective effect). </li><li>There may be an increased risk of menorrhagia with the Cu-IUD. </li><li>Surgical sterilization in women is associated with increased risk of pulmonary, cardiac, and neurological complications, and a possible increased risk of wound infections. Women with sickle cell disease who desire sterilization should receive appropriate counselling.</li><li>In men with sickle cell disease, there is no medical reason to deny vasectomy.</li></ul></li></ul></li><li><strong>Natural family planning methods</strong> may not be appropriate for women with sickle cell disease because of their relatively higher typical-use failure rates.</li></ul><!-- end field a84a008c-cb65-4a6d-81a3-9bddf4b67679 --><!-- end item 02807768-3fc4-433f-b0ff-ec9abe4bd5b0 -->","subChapters":[{"id":"1d0f10c7-9232-5fe9-b0e2-f430ed2443db","slug":"basis-for-recommendation-446","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 897bc35c-3306-4c1e-af4d-ea0d561770b8 --><h4>Basis for recommendation</h4><!-- end field 897bc35c-3306-4c1e-af4d-ea0d561770b8 -->","summary":null,"htmlStringContent":"<!-- begin item 446ec3b6-0e1e-4b8b-8117-fff05e0f18a9 --><!-- begin field 37f50720-c414-4a91-9c6c-9972e4e5c415 --><p>These recommendations are largely based on the<strong> </strong><em>UK Medical Eligibility Criteria for Contraceptive Use </em>published by the Faculty of Sexual and Reproductive Health Care (FSRH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>] and the World Health Organization (WHO) <em>Medical Eligibility Criteria for Contraceptive Use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">WHO, 2015</a>].</p><h5>Choice of contraception</h5><ul><li><strong>Combined hormonal contraception (pill, patch, and vaginal ring) </strong><ul><li>The UK eligibility criteria consider that sickle cell disease is 'a condition where the advantages of using the method generally outweigh the theoretical or proven risks' with respect to the use of a combined hormonal contraception (that is, category 2). However, pulmonary hypertension is 'a condition which represents an unacceptable health risk if the method is used' (category 4) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>]. </li><li>According to the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Management of sickle cell disease in pregnancy</em>, prescribers been reluctant to recommend the combined oral contraceptive (COC) pill in women with sickle cell disease, due to concerns about an increased risk of venous thromboembolism (VTE). However, there is no evidence using definitive outcome points of VTE to confirm this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">RCOG, 2011</a>]. Expert opinion in the <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society is that there is no additional risk of thrombotic adverse effects in women with sickle cell disease using COCs at the currently recommended doses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>]. </li></ul></li><li><strong>Progestogen-only contraception (pill, implant, and injection)</strong><ul><li>The UK eligibility criteria consider that sickle cell disease is 'a condition for which there is no restriction for the use of the contraceptive method' with respect to the use of progestogen-only contraception (that is, category 1) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>]. </li></ul></li><li><strong>The copper-bearing intrauterine devices (Cu-IUDs) and the </strong><strong>levonorgestrel-releasing intrauterine system (LNG-IUS)</strong><ul><li>The UK eligibility criteria consider that sickle cell disease is 'a condition where the advantages of using the method generally outweigh the theoretical or proven risks' with respect to the use of the Cu-IUD (that is, category 2). However, there is concern about an increased risk of blood loss with this method [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>].</li><li>The UK eligibility criteria consider that sickle cell disease is 'a condition for which there is no restriction for the use of the contraceptive method' with respect to the use of the LNG-IUS (that is, category 1). However, pulmonary hypertension is 'a condition where the advantages of using the method generally outweigh the theoretical or proven risks' (that is, category 2) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>].</li></ul></li><li><strong style=\"line-height: 1.6;\">Surgical sterilization</strong><ul><li>The UK eligibility criteria does not cover surgical sterilization [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>], and the FSRH guideline <em>Male and female sterilization</em> does not make recommendations for people with sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2014</a>].</li><li>The WHO eligibility criteria consider that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">WHO, 2015</a>]:<ul><li>Sickle cell disease is cause for female sterilization to be 'normally conducted in a routine setting, but with extra preparation and precautions' (that is, category C).</li><li>For sterilization of men with sickle cell disease, 'there is no medical reason to deny sterilization to a person with this condition' (that is, category A).</li><li>There is an increased risk of pulmonary, cardiac, or neurologic complications and possible increased risk of wound infection.</li></ul></li></ul></li><li><strong>Barrier methods</strong><ul><li>The UK eligibility criteria do not make specific recommendations on the barrier methods of contraception [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>], and the FSRH guideline <em>Barrier methods for contraception and STI prevention</em> does not make recommendations for people with sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2015a</a>].</li><li>The WHO eligibility criteria consider that sickle cell disease is 'a condition for which there is no restriction for the use of the contraceptive method' with respect to the use of barrier contraception (that is, category 1), but state that women with conditions that make pregnancy an unacceptable risk (such as sickle cell disease) should be advised that barrier methods may not be appropriate for those who cannot use them consistently and correctly, because of their relatively higher typical-use failure rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">WHO, 2015</a>].</li></ul></li></ul><h5>Advising the woman to consider using a long-acting reversible contraception (LARC) method</h5><ul><li>This recommendation is based on the UK eligibility criteria and the WHO eligibility criteria, which state that the sole use of barrier methods and user-dependent methods of contraception (such as oral contraception) may not be the most appropriate choice for women with conditions that may pose a significant health risk during pregnancy (such as sickle cell disease) given their relatively higher typical-use failure rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">WHO, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>].</li></ul><h5>Natural family planning</h5><ul><li><p>The UK eligibility criteria does not cover natural family planning [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2016</a>]. The FSRH guideline <em>Fertility awareness methods</em> does not make specific recommendations for women with sickle cell disease, but states that in women for whom pregnancy poses a significant health risk, the reliance on fertility indicators for the prevention of pregnancy is not recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">FSRH, 2015b</a>].</p></li><li><p>This is in line with the WHO eligibility criteria, which state that women with conditions that make pregnancy an unacceptable risk (such as sickle cell disease) should be advised that the fertility awareness-based (FAB) method and the lactational amenorrhoea method (LAM) may not be appropriate for them because of the relatively higher typical-use failure rates of these methods of contraception [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">WHO, 2015</a>].</p></li></ul><!-- end field 37f50720-c414-4a91-9c6c-9972e4e5c415 --><!-- end item 446ec3b6-0e1e-4b8b-8117-fff05e0f18a9 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}